{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:35:18Z","timestamp":1648560918645},"reference-count":7,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/naika.102.2426","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T23:18:00Z","timestamp":1410304680000},"page":"2426-2432","source":"Crossref","is-referenced-by-count":0,"title":["11. Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO)"],"prefix":"10.2169","volume":"102","author":[{"given":"Kazuo","family":"Fujihara","sequence":"first","affiliation":[{"name":"Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Osoegawa M, et al: Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 15: 159-173, 2009.","DOI":"10.1177\/1352458508098372"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Polman CH, et al: Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the "McDonald Criteria". Ann Neurol 69: 292-302, 2011.","DOI":"10.1002\/ana.22366"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cohen JA, Rudick RA: Multiple Sclerosis Therapeutics (4th edition). Cambridge University Press, 2011.","DOI":"10.1017\/CBO9781139023986"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lennon VA, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004.","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Wingerchuk DM, et al: The spectrum of neuromyelitis optica. Lancet Neurol 9: 805-815, 2007.","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fujihara K, et al: Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58-73, 2012.","DOI":"10.1111\/j.1759-1961.2012.00030.x"},{"key":"7","unstructured":"7) Kimbrough DJ, et al: Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1: 180-187, 2012."}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/9\/102_2426\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T16:58:39Z","timestamp":1621443519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/9\/102_2426\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.102.2426","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}